A study on language impairment following a stroke
This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.
Participants must meet the following criteria:
- Native English speaker
- Able to have an MRI
- Had only one stroke (in the left hemisphere of the brain)
The purpose of this study is to better understand the way the brain works in people who have depression and people who have previously been depressed. We are also testing healthy subjects for comparison. We hope our findings will lead to better ways to diagnose and treat mood disorders in the future. Participation involves an initial phone call and a 2 to 4 hour visit to find out if you are eligible. This visit will include completing questionnaires and interviews. If eligible, participants will have a second 3-5 hour visit for an MRI scan. Two months after the scan, participants will complete daily online questionnaires for 7 days. This process is repeated 2 months later (4 months after the scan). Participants can make up to $220 for full participation.
You may be eligible for this study if you: • Are between the ages of 18-40 • Are right-handed • Do not have a history of neurological disorders (e.g., seizures, head injury, etc.) • Do not have major medical problems (e.g., stroke, heart disease, high blood pressure, endocrine disorders, etc.) • Have normal vision, vision that is corrected to normal with glasses or contacts • Are willing and able to undergo fMRI scanning (not claustrophobic, no non-removable metal in your body) • Are not pregnant
Cognition and Brain Circuitry
The purpose of the study is to look at how our brain networks interact for different mental functions and how individual differences in brain structure and function determines individual differences in behavior. During this study, we use magnetic resonance imaging methods: functional magnetic resonance imaging (fMRI) and diffusion weighted imaging (DWI). Functional MRI (fMRI) and DWI are typical imaging methods that use a strong magnetic field and radio waves to make pictures of your body. The total length of the study will be between 3 and 4 hours, including up to 2 hours outside the MRI scanner and 2 hours in the scanner.
- Healthy adults between 18-40 years of age - Have normal or corrected-to-normal vision
Learning and Improving Alzheimer's Patient-Caregiver Relationships
The purpose of this study is to explore how family caregivers and persons with memory loss communicate and if certain ways of handling stress, such as mindfulness-based self managements, are helpful for family caregivers. You will be in the study for up to four months from the time of consent to the time of final study data collection. There will be 4 telephone or video calls, and each will take approximately 30 – 135 minutes.
Caregivers who will participate in this study need to: 1) be aged 21 years or older 2) be an informal, unpaid caregiver who lives with the care recipient 3) be fluent in English 4) have functioning home Wifi The inclusion criteria for care recipients (persons with memory loss) are: 1) females and males age 60-99 years 2) history of memory loss 3) community-dwelling (living in the home) 4) fluent in English
A Study to Evaluate the Connection Between the Brain and Behavior in Adults
The purpose of the study is to investigate how different parts of the brain are wired together and how they interact to form complex human behavior, and how our brain’s design makes each of us unique individuals. Different types of imaging methods - functional magnetic resonance imaging (fMRI ) and diffusion weighted imaging (DWI), imaging methods that use a strong magnetic field and radio waves to make pictures of your body, will be used to gather information from participants. No X-rays or other radiation is used in fMRI or DWI. Eye movements may be tracked as well, and you will be asked to respond to various conditions, questions, and stimuli.
- Must be between 18-45 years of age
Vercise™ DBS Registry
The purpose of this study is to record the personal experiences of those who have had Deep Brain Stimulation (DBS) using the Vercise™ System, for the treatment of Parkinson's Disease.
You may be eligible if you are:
- At least 18 years of age
- Planning to receive the currently available Vercise™ System and/or any new commercially approved parts such as leads, extension, Adaptor, CP, etc. that is works with the Vercise System
Abbott DBS (Deep Brain Stimulation) Registry
The purpose of this study is to collect information and evaluate outcomes for Abbott Deep Brain Stimulation (DBS) systems that are approved and sold in your country.
In order to evaluate how the DBS system performs, data will be collected before, during and after DBS implant when you visit the study doctor. The data collected will include information on your movements, feelings, daily activities, and DBS program settings.
The information gathered in this study will add to the understanding of treatment options for future patients receiving DBS.
- You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months
- You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
- You have another disease, conditions, or other medical, social, or psychological conditions that could limit the your ability to participate in the clinical investigation or to satisfy follow-up requirements
Evaluating Brain Reactivity in Response to One-Time Medication Use
This study looks at how brain response to emotional cues affects behavior. This research is being done to better understand the brain and behavior system in young adults in order to help develop interventions in the future. To participate in this study you will need to come to the OSU campus 3 times over a 2-3 week period. Each visit will last from about 2 to 5 hours.
Inclusion Criteria: - Adults ages 18-30 years of age - must be right-handed Exclusion Criteria:* - currently pregnant (positive pregnancy test), currently not using contraceptives, nursing, or trying to become pregnant - deafness in either ear - left handed * not a complete list of exclusion criteria
A Study to Evaluate an Investigational Drug (NLY01)Treatment to be used in Early-Stage Parkinson’s Disease
This research is studying a new drug, NLY01, in a large number of persons to learn about its effects in people with early-stage Parkinson’s disease (PD). Researchers want to know whether NLY01 helps lessen symptoms and signs of early PD, as well as slow the progression of the disease.
You will have a 2 in 3 chance of receiving NLY01 and a 1 in 3 chance of receiving a placebo, sterile salt water that looks like NLY01 but does not contain the study drug.
The total amount of time for you to be in the study will be approximately 45 to 54 weeks.
- Man or woman, at least 30 to 80 years old
- Have early-stage Parkinson's disease
- Not be on any current treatments for PD
- If of reproductive potential, willing and able to use a highly effective form of birth control during the study and for 30 days following last dose of study material
* Other criteria for eligibility apply
- Diagnosis of secondary or atypical parkinsonism
- Onset of any parkinsonian motor sign or symptom >5 years before Screening Visit
- Previous surgical procedure for PD
- Clinically significant medical, surgical, psychiatric, or laboratory abnormality
- Has an ECG or clinical evidence of potentially unstable heart disease
- Medical or recreational use of marijuana or THC-containing compounds within 3 months of the Screening Visit
* Other criteria for exclusion apply
A Study to Evaluate an Investigational Drug (tavapadon) as a Possible Treatment in Early Parkinson’s Disease
The main purpose of this study is to learn how well tavapadon (the study drug) works as a possible treatment for Parkinson’s disease and how safe the study drug is. The target dose range of tavapadon being studied is 5 to 15 mg once daily.
If you choose to participate in this study, you may receive the study drug, or you may receive placebo. A placebo is an inactive material, such as a sugar pill, that looks like the study drug but does not contain any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
You will be in this study for approximately 35 weeks, which includes a screening visit and safety follow up, and you will need to come to the study center at least 11 times over this period.
You may be eligible if you:
• Are Between the ages of 40 to 80 years
• Are willing to practice effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial if you are a sexually active man or woman of childbearing potential
• Were diagnosed more than 3 years ago
• Willing and able to not use any PD medications that are not permitted by the protocol (including dopaminergic agents) throughout participation in the trial.
You will be excluded if you:
• Have a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or post-stroke parkinsonism).
• Have had previous surgical intervention (eg, deep brain stimulation) for PD or for whom such a procedure is planned or anticipated during the trial period.
• Have hypertension.
• Have previously participated in any tavapadon trial, including this trial, and received IMP.
• Have received treatment with any other investigational drug within 60 days before signing the ICF.